Diversity and inclusion in clinical trials are paramount for ethical and effective advancement of medical research. Inclusion involves actively engaging individuals from various demographic backgrounds, including age, gender, ethnicity, socioeconomic status, and geographic location. Aneurysmal SAH affects women and racial ethnic minorities more than others, underscoring the significance of ensuring diversity in BLOCK-SAH. By incorporating diverse perspectives and experiences, we can better understand how different groups respond to the active treatment, ultimately leading to more personalized and equitable healthcare outcomes. This will also help us address longstanding disparities in healthcare access and outcomes. In BLOCK-SAH, we are committed to actively address barriers that may prevent underrepresented groups from participating in clinical trials, such as language barriers and mistrust. We guarantee equitable access to standardized healthcare and thorough safety measures for all participants without discrimination.